Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
  • inderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

Spermosens announces last day of trading for warrants of series TO 4

Spermosens
Ladda ner börsmeddelandet

Spermosens AB ("Spermosens" or "the Company") announces that the last day of trading for the warrants of series TO 4 on Spotlight Stock Market is 27 November 2025.

The warrants of series TO 4 were issued in connection with the rights issue announced on 20 February 2024, with a subscription period that ended on 17 April 2024. Each warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.15. The exercise period for the warrants runs from 17 November 2025 to 1 December 2025.

The subscription price of SEK 0.15 was determined before the issuance of new shares in the separate rights issue carried out in November 2024. Based on the current share price, the warrants are considered to be out of the money, meaning that the subscription price, taking into account the effect of a customary recalculation exceeds the market price of the Company's share.

For more information, please visit www.spermosens.com.

For further information, please contact:
Tore Duvold, CEO
Email: info@spermosens.com

 

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science-driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision in evaluations by measuring sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatment strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.

 

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.